These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 36594582)

  • 1. Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Tong X; Li M; Jin J; Li Y; Li L; Peng Y; Huang L; Xu B; Meng F; Mao X; Huang L; Huang W; Zhang D
    Int J Cancer; 2023 May; 152(10):2123-2133. PubMed ID: 36594582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect and safety of 10-day decitabine-containing conditioning regimen for allogeneic hematopoietic stem cell transplantation in 31 patients with acute myeloid leukemia/myelodysplastic syndrome].
    Liu J; Cao YG; Zhang RL; Zhai WH; Chen X; Ma QL; Pang AM; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):472-478. PubMed ID: 37550202
    [No Abstract]   [Full Text] [Related]  

  • 3. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
    Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of cladribine in combination with busulfan and cyclophosphamide as an intensive conditioning regimen preceding allogeneic hematopoietic stem cell transplantation in relapsed or refractory acute myeloid leukemia.
    Xiao F; Guo H; Yan X; Qi M; Zhang J
    Transpl Immunol; 2024 Jun; 84():102037. PubMed ID: 38499049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation with Decitabine-containing Regimen in Myelodysplastic Syndromes and Myelodysplastic Syndromes Transformed Acute Myeloid Leukemia].
    Wang YX; Sun Y; Xie J; Liu N; Hu JW; Qiao ZQ; Lan SC; Zhao L; Yang Y; Li YH; Zhang B; Hu LD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):522-531. PubMed ID: 37096529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and Safety of Cladribine-based Intensified Conditioning Regimen in Hematopoietic Stem Cell Transplantation in Patients with High-Risk Acute Myeloid Leukemia].
    Pan WY; Li KX; Wu HY; He YZ; DU JW; Zheng YL; Tu SF; Song CY; Li YH; Huang YX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):65-71. PubMed ID: 35123605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical observation of 12 patients with refractory/relapsed acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation containing cladribine regimen].
    Ai H; Fu YW; Wang YQ; Wei XD; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2019 Oct; 40(10):827-830. PubMed ID: 31775481
    [No Abstract]   [Full Text] [Related]  

  • 8. [Decitabine-based conditioning regimen is feasible and effective in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia].
    Zhao XL; Jiang EL; Zhai WH; Ma QL; Pang AM; Wei JL; He Y; Yang DL; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):467-471. PubMed ID: 31340618
    [No Abstract]   [Full Text] [Related]  

  • 9. [Combination of busulfan with increased-dose of fludarabine as conditioning regimen for MDS and MDS-AML patients with allo-HSCT].
    Yuan J; Ren H; Qiu Z; Li Y; Wang M; Liu W; Xu W; Sun Y; Wang L; Liang Z; Dong Y; Ou J; Wang W; Yin Y; Cen X; Wang Q
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jun; 36(6):475-9. PubMed ID: 26134011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Myeloproliferative Neoplasms.
    Cao YG; He Y; Zhang SD; Liu ZX; Zhai WH; Ma QL; Pang AM; Wei JL; Yang DL; Huang Y; Feng SZ; Jiang EL; Han MZ
    Biol Blood Marrow Transplant; 2020 Feb; 26(2):285-291. PubMed ID: 31494229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.
    Hoff FW; Chung SS; Patel PA; Premnath N; Khatib J; Tadic-Ovcina M; AhmedRabie A; Helton D; Yohannes S; Shahan J; Patel H; Geethakumari PR; Vusirikala M; Collins RH; Madanat YF
    Transpl Immunol; 2023 Apr; 77():101808. PubMed ID: 36842566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CLAG combined with total body irradiation as intensive conditioning chemotherapy prior to allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.
    Fei X; Zhang W; Gu J; Yang F; Li T; Wang W; Wang J
    Ann Hematol; 2024 Jan; 103(1):241-249. PubMed ID: 37847380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of CLAE Chemotherapy Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia].
    Tao SD; Song LX; Deng Y; Chen Y; Zhang X; Ding BH; Wang CL; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):677-684. PubMed ID: 37356926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of Decitabine Therapeutic Effeicacy for Patients with Relapsed MDS/AML and High-Risk AML Patients after HSCT].
    Wang QY; Liang ZY; Dong YJ; Yin Y; Wang Q; Liu W; Xu WL; Li Y; Ren HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):248-254. PubMed ID: 32027285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
    Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
    [No Abstract]   [Full Text] [Related]  

  • 17. Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus Host Disease.
    Wang QY; Li Y; Liang ZY; Yin Y; Liu W; Wang Q; Dong YJ; Sun YH; Xu WL; Ren HY
    Cancer Manag Res; 2019; 11():10195-10203. PubMed ID: 31824191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
    BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation.
    Zhu J; Wang Q; Ren H; Dong Y; Yin Y; Wang Q; Liang Z; Liu W; Wang Q; Wang B; Li Y
    Front Immunol; 2023; 14():1274492. PubMed ID: 37928518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia].
    Wang Y; Liu KY; Xu LP; Liu DH; Chen H; Han W; Chen YH; Shi HX; Zhang YC; Wang JZ; Zhang XU; Chen Y; Huang XJ; Lu DP
    Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):903-6. PubMed ID: 18261271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.